GSK cutting 720 jobs in manufacturing, R&D and support functions at massive Belgian vaccine hub

GlaxoSmithKline’s vaccines unit has been a bright spot for the company amid challenges elsewhere, but its recent performance doesn’t make it immune to staff cuts. The drugmaker this week unveiled a restructuring and up to 720 layoffs.